CN102552891A - 热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法 - Google Patents
热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法 Download PDFInfo
- Publication number
- CN102552891A CN102552891A CN2011104478076A CN201110447807A CN102552891A CN 102552891 A CN102552891 A CN 102552891A CN 2011104478076 A CN2011104478076 A CN 2011104478076A CN 201110447807 A CN201110447807 A CN 201110447807A CN 102552891 A CN102552891 A CN 102552891A
- Authority
- CN
- China
- Prior art keywords
- cell
- heat shock
- tumor
- apoptosis
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 23
- 230000035939 shock Effects 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229960005486 vaccine Drugs 0.000 title claims abstract description 13
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 12
- 206010018338 Glioma Diseases 0.000 title claims abstract description 12
- 208000017815 Dendritic cell tumor Diseases 0.000 title claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000000427 antigen Substances 0.000 claims abstract description 24
- 102000036639 antigens Human genes 0.000 claims abstract description 24
- 108091007433 antigens Proteins 0.000 claims abstract description 24
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 21
- 102100022297 Integrin alpha-X Human genes 0.000 claims abstract description 18
- 238000001514 detection method Methods 0.000 claims abstract description 13
- 230000001939 inductive effect Effects 0.000 claims abstract description 12
- 102100035793 CD83 antigen Human genes 0.000 claims abstract description 9
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims abstract description 9
- 102000006354 HLA-DR Antigens Human genes 0.000 claims abstract description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 claims abstract description 6
- 230000001640 apoptogenic effect Effects 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 8
- 208000024055 brain glioblastoma Diseases 0.000 claims description 7
- 201000011609 brain glioblastoma multiforme Diseases 0.000 claims description 7
- 230000030833 cell death Effects 0.000 claims description 6
- 230000002490 cerebral effect Effects 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 210000005259 peripheral blood Anatomy 0.000 claims description 6
- 239000002158 endotoxin Substances 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims description 3
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 3
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims description 3
- 229920001917 Ficoll Polymers 0.000 claims description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 claims description 3
- 238000012411 cloning technique Methods 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 3
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims description 3
- 238000004043 dyeing Methods 0.000 claims description 3
- 210000003677 hemocyte Anatomy 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims description 3
- 238000005192 partition Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 229940029030 dendritic cell vaccine Drugs 0.000 abstract description 13
- 102000002812 Heat-Shock Proteins Human genes 0.000 abstract description 11
- 108010004889 Heat-Shock Proteins Proteins 0.000 abstract description 11
- 230000028993 immune response Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000000684 flow cytometry Methods 0.000 abstract description 3
- 210000004443 dendritic cell Anatomy 0.000 abstract 4
- 101100341519 Homo sapiens ITGAX gene Proteins 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000009668 clonal growth Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011104478076A CN102552891A (zh) | 2011-12-27 | 2011-12-27 | 热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011104478076A CN102552891A (zh) | 2011-12-27 | 2011-12-27 | 热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102552891A true CN102552891A (zh) | 2012-07-11 |
Family
ID=46400343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011104478076A Pending CN102552891A (zh) | 2011-12-27 | 2011-12-27 | 热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102552891A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104491853A (zh) * | 2014-12-29 | 2015-04-08 | 深圳市赛欧细胞生物科技有限公司 | 一种人树突状细胞肿瘤疫苗的制备方法 |
CN111334471A (zh) * | 2020-03-27 | 2020-06-26 | 郑州鲲鹏健康科技有限公司 | Pbmc体外3d琼脂糖水凝胶培养基及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101052709A (zh) * | 2004-10-25 | 2007-10-10 | 贝勒研究院 | 装载热激黑素瘤细胞体的树突细胞 |
CN101918544A (zh) * | 2007-12-10 | 2010-12-15 | 因斯布鲁克医科大学 | 提高免疫反应性的方法 |
-
2011
- 2011-12-27 CN CN2011104478076A patent/CN102552891A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101052709A (zh) * | 2004-10-25 | 2007-10-10 | 贝勒研究院 | 装载热激黑素瘤细胞体的树突细胞 |
CN101918544A (zh) * | 2007-12-10 | 2010-12-15 | 因斯布鲁克医科大学 | 提高免疫反应性的方法 |
Non-Patent Citations (1)
Title |
---|
徐杰等: "热休克诱导凋亡的脑胶质瘤细胞负载树突状细胞及其激发T细胞的体外试验", 《苏州大学学报(医学版)》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104491853A (zh) * | 2014-12-29 | 2015-04-08 | 深圳市赛欧细胞生物科技有限公司 | 一种人树突状细胞肿瘤疫苗的制备方法 |
CN111334471A (zh) * | 2020-03-27 | 2020-06-26 | 郑州鲲鹏健康科技有限公司 | Pbmc体外3d琼脂糖水凝胶培养基及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103627672B (zh) | Nk细胞体外培养方法 | |
CN109294985A (zh) | 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法 | |
CN105950560A (zh) | 人源化pd-l1肿瘤细胞系及具有该细胞系的动物模型与应用 | |
TW201814041A (zh) | 用於病毒專一性t細胞之活化及增生的平台 | |
CN101824400B (zh) | 一种放大增殖抗原特异性t细胞的方法 | |
CN101481677B (zh) | 体外刺激树突状细胞成熟的方法 | |
JP6263559B2 (ja) | 従来型樹状細胞によるifn‐ラムダの産生及びその使用 | |
CN102600462A (zh) | 人树突状细胞肿瘤疫苗及其制备方法和应用 | |
CN103800898A (zh) | 一种肿瘤特异性杀伤细胞制剂及其制备方法 | |
CN103255105A (zh) | 一种使用dc细胞刺激cik细胞快速增殖的方法 | |
CN103301449A (zh) | 一种大规模培养树突状细胞疫苗的制备方法及其应用 | |
CN104498434A (zh) | 一种大量树突状细胞的制备方法、所得树突状细胞 | |
CN105112371A (zh) | 脐带血单个核细胞来源的dc-cik细胞制取方法及制剂 | |
CN104894072A (zh) | 一种自体自然杀伤细胞增殖的制备方法及其应用 | |
CN102746381B (zh) | 一种幽门螺杆菌抗原hla限制性免疫显性表位肽及其制备方法和应用 | |
CN102552891A (zh) | 热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法 | |
CN107158367A (zh) | 结直肠癌干细胞疫苗制备方法及应用 | |
US20220177839A1 (en) | Composition, culture medium and method for inducing and/or amplifying tscm in vitro | |
CN104017770B (zh) | 一种利用糖脂制备cik细胞的方法 | |
CN102559598A (zh) | 热休克凋亡脑胶质瘤细胞的制备与检测方法 | |
CN103013906B (zh) | 一种生物膜及其制备方法和应用 | |
CN107574149B (zh) | 一种树突状细胞的促成熟方法及其用途 | |
CN104434973A (zh) | 一种强化细胞因子诱导的杀伤细胞功能的方法 | |
CN106047810A (zh) | 一种新型DC‑CTLs细胞培养体系及其培养方法 | |
Sjaastad et al. | Reduced T Cell Priming in Microbially Experienced “Dirty” Mice Results from Limited IL-27 Production by XCR1+ Dendritic Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU MAIJIAN BIO-TECH. DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: LU HUA Effective date: 20130725 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Lu Hua Inventor after: Chang Jing Inventor before: Lu Hua |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 214000 WUXI, JIANGSU PROVINCE TO: 214043 WUXI, JIANGSU PROVINCE Free format text: CORRECT: INVENTOR; FROM: LU HUA TO: LU HUA CHANG JING |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130725 Address after: 214043, Jiangsu, Wuxi province Beitang District No. 401 North Hing Yuen Road, north science and Technology Park, room 836 Applicant after: Jiangsu Maijian Bio-tech Development Co.,Ltd. Address before: 214000 Jinshan north science and Technology Industrial Park, No. 888 Jianghai West Road, Jiangsu, Wuxi Applicant before: Lu Hua |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120711 |